Two papers have been published regarding to the iPLAT1 (The first-in-human clinical trial of iPSC-derived platelets). Please refer to the prerelease on CiRA HP

iPLAT1: The first-in-human clinical trial of iPSC-derived platelets as a phase 1 autologous transfusion study. Blood. 2022 Sep 16: blood. 2022017296. doi: 10.1182/blood.2022017296.

Production and nonclinical evaluation of an autologous iPSC-deriveplatelet product for the iPLAT1 clinical trial. Blood Adv. 2022 Sep bloodadvances.2022008512. doi: 10.1182/bloodadvances.2022008512.